Zomedica Corp.

Equities

ZOM

CA98980M1095

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
0.142 ^USD	+0.28%		+9.15%	-29.07%

Apr. 01	Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 01	Zomedica Seeks Acquisitions	CI

Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024

March 06, 2024 at 08:14 am EST

ANN ARBOR - Zomedica Corp. (NYSE American: ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti Small Cap Conference, taking place virtually on March 14th, 2024.

The Company's presentation will take place at 10:00 am ET on Thursday, March 14, 2024, and can be accessed directly on the official Sidoti Conference website.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care.

Contact:

Email: investors@zomedica.com

Tel: 1-734-369-2555

Latest news about Zomedica Corp.

Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Zomedica Seeks Acquisitions	Apr. 01	CI
Transcript : Zomedica Corp., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Earnings Flash (ZOM) ZOMEDICA Posts Q4 Revenue $7.3M	Apr. 01	MT
Zomedica Corp. Reiterates Revenue Guidance for Full Year 2024	Apr. 01	CI
Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay Platform	Mar. 14	CI
Transcript : Zomedica Corp. - Shareholder/Analyst Call	Feb. 28
Transcript : Zomedica Corp. - Analyst/Investor Day	Feb. 13
Zomedica Pharmaceuticals Reports Preliminary Q4 Revenue	Jan. 17	MT
Transcript : Zomedica Corp., 2023 Sales/ Trading Statement Call, Jan 17, 2024	Jan. 17
Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024	Jan. 17	CI
Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease	Dec. 18	CI
Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy	Dec. 06	CI
Earnings Flash (ZOM) ZOMEDICA Posts Q3 Revenue $6.3M	Nov. 13	MT
Transcript : Zomedica Corp., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Zomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Zomedica Corp. acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc. for $11.3 million.	23-10-04	CI
Zomedica Corp. Launches its Newest Assay - Endogenous ACTH	23-09-14	CI
Zomedica Pharmaceuticals Issued Warning From NYSE American For Failing to Meet Listing Requirement	23-09-13	MT
Zomedica Completes Acquisition of Structured Monitoring Products	23-09-05	MT
Earnings Flash (ZOM) ZOMEDICA Posts Q2 Revenue $6M	23-08-10	MT
Zomedica Seeks M&A Opportunities	23-08-10	CI
Transcript : Zomedica Corp., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Zomedica Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Zomedica Corp. - Shareholder/Analyst Call	23-06-13

Chart Zomedica Corp.

Duration

Period

More charts

Company Profile

Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.

Sector

Healthcare Facilities & Services

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar